PEN

Penumbra, Inc.
CAPPED RATING

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Penumbra, Inc. (PEN) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Value (D+). The rating has held at C for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
D+
Factor Score 1.6 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
D+
Factor Score 1.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 80.8
EV / EBITDA 58.3
Rev Growth YoY 15.6%
Gross Margin 68.0%
Price Return 3M -1.9%
Price Return 12M 14.5%
Catalyst Signal +0.02
Market Cap $12.6B
TTM Revenue $1.6B
Price / Sales 8.1
ROE 10.7%

Historical Factor Score Progression

Held C for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 D+ (1.6) C (2.3) B+ (3.6) B- (3.1) D+ (1.6) C (2.4)
2026-11-09 D (1.5) C (2.3) B+ (3.6) B- (3.1) D+ (1.6) C (2.4)
2026-11-02 D+ (1.5) C (2.3) B+ (3.6) B- (3.0) D+ (1.6) C (2.4)
2026-11-01 D+ (1.6) C (2.2) B+ (3.6) C+ (2.8) D+ (1.7) C (2.4)
2026-10-26 D+ (1.6) C (2.2) B+ (3.6) C+ (2.8) C- (2.1) C (2.5)
Page 1 of 8
…